Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900106816> ?p ?o ?g. }
- W2900106816 endingPage "326" @default.
- W2900106816 startingPage "314" @default.
- W2900106816 abstract "Matriptase is a member of the type-II transmembrane serine protease (TTSP) family and plays a crucial role in the development and maintenance of epithelial tissues. As all chymotrypsin-like serine proteases, matriptase is synthesized as a zymogen (proform), requiring a cleavage event for full activity. Recent studies suggest that the zymogen of matriptase possesses enough catalytic activity to not only facilitate autoactivation, but also carry out its in vivo functions, which include activating several proteolytic and signaling cascades. Inhibition of zymogen matriptase may therefore be a highly effective approach for limiting matriptase activity. To this end, here we sought to characterize the catalytic activity of human zymogen matriptase and to develop mAb inhibitors against this enzyme form. Using a mutated variant of matriptase in which the serine protease domain is locked in the zymogen conformation, we confirmed that the zymogen form of human matriptase has catalytic activity. Moreover, the crystal structure of the catalytic domain of zymogen matriptase was solved to 2.5 Å resolution to characterize specific antibody-based matriptase inhibitors and to further structure-based studies. Finally, we describe the first antibody-based competitive inhibitors that target both the zymogen and activated forms of matriptase. We propose that these antibodies provide a more efficient way to regulate matriptase activity by targeting the protease both before and after its activation and may be of value for both research and preclinical applications. Matriptase is a member of the type-II transmembrane serine protease (TTSP) family and plays a crucial role in the development and maintenance of epithelial tissues. As all chymotrypsin-like serine proteases, matriptase is synthesized as a zymogen (proform), requiring a cleavage event for full activity. Recent studies suggest that the zymogen of matriptase possesses enough catalytic activity to not only facilitate autoactivation, but also carry out its in vivo functions, which include activating several proteolytic and signaling cascades. Inhibition of zymogen matriptase may therefore be a highly effective approach for limiting matriptase activity. To this end, here we sought to characterize the catalytic activity of human zymogen matriptase and to develop mAb inhibitors against this enzyme form. Using a mutated variant of matriptase in which the serine protease domain is locked in the zymogen conformation, we confirmed that the zymogen form of human matriptase has catalytic activity. Moreover, the crystal structure of the catalytic domain of zymogen matriptase was solved to 2.5 Å resolution to characterize specific antibody-based matriptase inhibitors and to further structure-based studies. Finally, we describe the first antibody-based competitive inhibitors that target both the zymogen and activated forms of matriptase. We propose that these antibodies provide a more efficient way to regulate matriptase activity by targeting the protease both before and after its activation and may be of value for both research and preclinical applications." @default.
- W2900106816 created "2018-11-16" @default.
- W2900106816 creator A5006543959 @default.
- W2900106816 creator A5011753158 @default.
- W2900106816 creator A5026679287 @default.
- W2900106816 creator A5034893892 @default.
- W2900106816 creator A5035557355 @default.
- W2900106816 creator A5047355282 @default.
- W2900106816 creator A5055300726 @default.
- W2900106816 creator A5064050035 @default.
- W2900106816 creator A5075811004 @default.
- W2900106816 creator A5081015046 @default.
- W2900106816 date "2019-01-01" @default.
- W2900106816 modified "2023-10-17" @default.
- W2900106816 title "Blocking the proteolytic activity of zymogen matriptase with antibody-based inhibitors" @default.
- W2900106816 cites W1946659263 @default.
- W2900106816 cites W1975233559 @default.
- W2900106816 cites W1978123763 @default.
- W2900106816 cites W1991757994 @default.
- W2900106816 cites W1993326158 @default.
- W2900106816 cites W2011484328 @default.
- W2900106816 cites W2013673267 @default.
- W2900106816 cites W2016021454 @default.
- W2900106816 cites W2016342555 @default.
- W2900106816 cites W2016382201 @default.
- W2900106816 cites W2020745334 @default.
- W2900106816 cites W2026497502 @default.
- W2900106816 cites W2027151401 @default.
- W2900106816 cites W2028351310 @default.
- W2900106816 cites W2030522563 @default.
- W2900106816 cites W2039135880 @default.
- W2900106816 cites W2051462955 @default.
- W2900106816 cites W2061345205 @default.
- W2900106816 cites W2063572236 @default.
- W2900106816 cites W2068978255 @default.
- W2900106816 cites W2082547107 @default.
- W2900106816 cites W2094592690 @default.
- W2900106816 cites W2097019319 @default.
- W2900106816 cites W2108038768 @default.
- W2900106816 cites W2113558240 @default.
- W2900106816 cites W2115573646 @default.
- W2900106816 cites W2119542456 @default.
- W2900106816 cites W2125455047 @default.
- W2900106816 cites W2136212775 @default.
- W2900106816 cites W2137428220 @default.
- W2900106816 cites W2253015953 @default.
- W2900106816 cites W2345596619 @default.
- W2900106816 cites W2555913424 @default.
- W2900106816 cites W2573789295 @default.
- W2900106816 cites W2600520855 @default.
- W2900106816 cites W2620610555 @default.
- W2900106816 cites W2790046231 @default.
- W2900106816 doi "https://doi.org/10.1074/jbc.ra118.004126" @default.
- W2900106816 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6322904" @default.
- W2900106816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30409910" @default.
- W2900106816 hasPublicationYear "2019" @default.
- W2900106816 type Work @default.
- W2900106816 sameAs 2900106816 @default.
- W2900106816 citedByCount "9" @default.
- W2900106816 countsByYear W29001068162019 @default.
- W2900106816 countsByYear W29001068162020 @default.
- W2900106816 countsByYear W29001068162021 @default.
- W2900106816 countsByYear W29001068162022 @default.
- W2900106816 countsByYear W29001068162023 @default.
- W2900106816 crossrefType "journal-article" @default.
- W2900106816 hasAuthorship W2900106816A5006543959 @default.
- W2900106816 hasAuthorship W2900106816A5011753158 @default.
- W2900106816 hasAuthorship W2900106816A5026679287 @default.
- W2900106816 hasAuthorship W2900106816A5034893892 @default.
- W2900106816 hasAuthorship W2900106816A5035557355 @default.
- W2900106816 hasAuthorship W2900106816A5047355282 @default.
- W2900106816 hasAuthorship W2900106816A5055300726 @default.
- W2900106816 hasAuthorship W2900106816A5064050035 @default.
- W2900106816 hasAuthorship W2900106816A5075811004 @default.
- W2900106816 hasAuthorship W2900106816A5081015046 @default.
- W2900106816 hasBestOaLocation W29001068161 @default.
- W2900106816 hasConcept C170493617 @default.
- W2900106816 hasConcept C181199279 @default.
- W2900106816 hasConcept C182220744 @default.
- W2900106816 hasConcept C185592680 @default.
- W2900106816 hasConcept C24530287 @default.
- W2900106816 hasConcept C2776414213 @default.
- W2900106816 hasConcept C2776714187 @default.
- W2900106816 hasConcept C2777807008 @default.
- W2900106816 hasConcept C2778775115 @default.
- W2900106816 hasConcept C55493867 @default.
- W2900106816 hasConcept C86803240 @default.
- W2900106816 hasConcept C95444343 @default.
- W2900106816 hasConceptScore W2900106816C170493617 @default.
- W2900106816 hasConceptScore W2900106816C181199279 @default.
- W2900106816 hasConceptScore W2900106816C182220744 @default.
- W2900106816 hasConceptScore W2900106816C185592680 @default.
- W2900106816 hasConceptScore W2900106816C24530287 @default.
- W2900106816 hasConceptScore W2900106816C2776414213 @default.
- W2900106816 hasConceptScore W2900106816C2776714187 @default.
- W2900106816 hasConceptScore W2900106816C2777807008 @default.
- W2900106816 hasConceptScore W2900106816C2778775115 @default.
- W2900106816 hasConceptScore W2900106816C55493867 @default.